Michael D. Wendt
Protein-Protein Interactions as Drug Targets

Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Kurt Deshayes , Jeremy Murray , Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection

Nicholas A. Meanwell , David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion a Focus on Respiratory Syncytial Virus

Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor

In each volume an overview chapter introduces the newcomer to the topic covered Series covers hot topics of frontier research summarized by reputed scientists in the field Review series is topic related Includes supplementary material: sn.pub/extras

Klappentext

Michael D. Wendt
Protein-Protein Interactions as Drug Targets

Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Kurt Deshayes , Jeremy Murray , Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection

Nicholas A. Meanwell , David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion a Focus on Respiratory Syncytial Virus

Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor

Inhalt

Protein-Protein Interactions as Drug Targets.- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer.- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection.- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion a Focus on Respiratory Syncytial Virus.- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces.- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor.